ciglitazone has been researched along with Cancer of Pituitary in 1 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bogazzi, F | 1 |
Ultimieri, F | 1 |
Raggi, F | 1 |
Russo, D | 1 |
Vanacore, R | 1 |
Guida, C | 1 |
Viacava, P | 1 |
Cecchetti, D | 1 |
Acerbi, G | 1 |
Brogioni, S | 1 |
Cosci, C | 1 |
Gasperi, M | 1 |
Bartalena, L | 1 |
Martino, E | 1 |
1 other study available for ciglitazone and Cancer of Pituitary
Article | Year |
---|---|
PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas.
Topics: Adenoma; Animals; Annexin A5; Apoptosis; Cell Line; DNA Fragmentation; Female; Gene Expression; Huma | 2004 |